- Home
- RXST vs PBYI Comparison
RXST vs PBYI Comparison
Compare RXST & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXST | PBYI |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.0M | 318.0M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | RXST | PBYI |
|---|---|---|
| Price | $6.59 | $6.38 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $11.60 | N/A |
| AVG Volume (30 Days) | ★ 620.4K | 413.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | ★ $134,479,000.00 | $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.57 | N/A |
| P/E Ratio | ★ N/A | $10.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.02 | $2.58 |
| 52 Week High | $27.13 | $7.68 |
Technical Indicators
Market Signals| Indicator | RXST | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 51.78 |
| Support Level | N/A | $6.32 |
| Resistance Level | $9.11 | $7.25 |
| Average True Range (ATR) | 0.41 | 0.20 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 30.10 | 79.39 |
Price Performance
Historical ComparisonAbout RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.